Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2022-11-15 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
北京神州细胞生物技术集团股份公司募集资金置换专项鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金置换专项鉴证报告" which translates to a "Special Verification Report on the Replacement of Raised Funds." It is issued by a certified public accountant firm and includes an independent verification opinion on the company's management-prepared special statement regarding the use of raised funds to replace self-raised funds previously invested in projects and paid issuance expenses. The document references regulatory guidelines related to the management and use of raised funds by listed companies, specifically citing the China Securities Regulatory Commission and Shanghai Stock Exchange regulations. The content includes detailed financial figures about the raised funds, their usage, and the replacement of self-raised funds, along with the auditor's verification and opinion. This is a standalone audit-related report focusing on a specific aspect of the company's fundraising and fund usage, not a full annual or interim report, nor a simple announcement. It is not a general regulatory filing or a report publication announcement because it contains substantive audit verification content and financial details. Therefore, the document fits the category of an Audit Report / Information (AR). Q4 2022
2022-11-15 Chinese
神州细胞关于对外捐赠的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding an external donation plan approved by the board of directors. It details the purpose, scope, and impact of the donation, emphasizing corporate social responsibility and compliance with regulatory requirements. The document is short (1356 characters), does not contain financial statements or detailed financial data, and is not a report but an announcement of a corporate action. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not related to board changes, voting results, or financing updates. The content aligns with a regulatory announcement about a corporate social responsibility activity. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2022-11-15 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司使用暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion report from a sponsoring institution (中信证券股份有限公司) regarding the use of temporarily idle raised funds by 北京神州细胞生物技术集团股份公司 for cash management. It references regulatory compliance with securities laws and stock exchange rules, discusses the amount, purpose, risk control, and approvals by the board, supervisory board, and independent directors. The document is not a full financial report but a formal verification and opinion on the use of raised funds, which aligns with an audit or regulatory compliance report rather than an annual or interim report. It is not a brief announcement or a proxy statement, nor is it a transcript or earnings release. The document length is 3813 characters, which is relatively short but contains substantive content and formal opinions. This fits best with the category of Audit Report / Information (AR), as it is a standalone audit-related opinion on the use of funds and compliance with regulations. FY 2022
2022-11-15 Chinese
神州细胞第二届监事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the meeting date, attendance, and voting results on proposals related to the use of raised funds and cash management. The content focuses on internal governance decisions and approvals rather than financial results, audit opinions, or regulatory filings. It is not an annual report, audit report, earnings release, or any financial statement. It is also not a notice of dividend, capital change, or share transactions. The document is a formal announcement of board-level decisions, fitting the category of Board/Management Information (MANG). The document length is short and contains detailed meeting resolutions, not just a brief announcement or certification, so it is not RNS or RPA. Therefore, the best classification is MANG with high confidence.
2022-11-15 Chinese
神州细胞关于使用暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the board and supervisory approvals, the amount and purpose of the cash management, risk control measures, and compliance with regulatory requirements. The document references the approval from the China Securities Regulatory Commission and the Shanghai Stock Exchange rules. It is not a financial report like an annual or interim report, nor is it a certification or voting result. It is a regulatory announcement about the company's capital management activities related to raised funds. The document length is 3394 characters, which is relatively short and focused on a specific financing-related update. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-11-15 Chinese
神州细胞关于控股子公司在澳大利亚设立全资子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding its controlling subsidiary's plan to establish a wholly-owned subsidiary in Australia. It details the investment amount, purpose, approval process, risks, and impact on the company. The text is an official announcement about a capital investment and establishment of a new subsidiary abroad, not a financial report or earnings release. It does not contain financial statements or detailed financial data, nor is it a report publication or certification. The content fits best under Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes, specifically an overseas investment and subsidiary establishment.
2022-11-15 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.